BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 19414425)

  • 1. Prognostic factors influencing tumor response, locoregional control and survival, in melanoma patients with multiple limb in-transit metastases treated with TNFalpha-based isolated limb perfusion.
    Di Filippo F; Giacomini P; Rossi CR; Santinami M; Anzà M; Garinei R; Perri P; Botti C; Di Angelo P; Sofra C; Pasqualoni R; Sperduti I; Cavaliere F; Di Filippo S; Corrias F; Armenti A; Ferraresi V; Ginebri A
    In Vivo; 2009; 23(2):347-52. PubMed ID: 19414425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.
    Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S
    In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperthermic antiblastic perfusion with TNFalpha and melphalan in stage III limb melanoma patients: A phase I - II SITILO study.
    Di Filippo F; Rossi CR; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S; Di Angelo P; Principi F; Laurenzi L
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):97-101. PubMed ID: 16767914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
    Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hyperthermic isolated perfusion with tumor necrosis factor-alpha and doxorubicin for the treatment of limb-threatening soft tissue sarcoma: the experience of the Italian Society of Integrated Locoregional Treatment in Oncology (SITILO).
    Di Filippo F; Giacomini P; Rossi CR; Santinami M; Garinei R; Anzà M; Deraco M; Botti C; Perri P; Cavaliere F; Di Angelo P; Sofra C; Sperduti I; Pasqualoni R; Di Filippo S; Corrias F; Armenti A; Ferraresi V
    In Vivo; 2009; 23(2):363-7. PubMed ID: 19414428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TNF-based limb perfusion for cutaneous melanoma in transit metastases: suggestions for modification of the perfusional schedule.
    Rossi CR; Foletto M; Mocellin S; Pilati PL; Campana L; Rubello D; Lise M
    J Exp Clin Cancer Res; 2003 Dec; 22(4 Suppl):103-7. PubMed ID: 16767915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
    Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
    Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isolated limb perfusion for in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
    Hoekstra HJ; Veerman K; van Ginkel RJ
    J Surg Oncol; 2014 Mar; 109(4):338-47. PubMed ID: 24403098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
    Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
    J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
    Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
    Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolated limb infusion for malignant melanoma: predictors of response and outcome.
    Barbour AP; Thomas J; Suffolk J; Beller E; Smithers BM
    Ann Surg Oncol; 2009 Dec; 16(12):3463-72. PubMed ID: 19830498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalan.
    Klaase JM; Kroon BB; van Geel AN; Eggermont AM; Franklin HR; Hart AA
    Surgery; 1994 Jan; 115(1):39-45. PubMed ID: 8284759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin D in melanoma patients.
    Kroon HM; Moncrieff M; Kam PC; Thompson JF
    Ann Surg Oncol; 2009 May; 16(5):1184-92. PubMed ID: 19224289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Merkel cell carcinoma: an unusual indication for isolated limb perfusion.
    Ponte P; Moniz JV; Farricha V; Weinholtz JB
    Dermatol Online J; 2008 Jul; 14(7):6. PubMed ID: 18718190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolated limb perfusion with melphalan and tumor necrosis factor alpha for advanced melanoma and soft-tissue sarcoma.
    Hayes AJ; Neuhaus SJ; Clark MA; Thomas JM
    Ann Surg Oncol; 2007 Jan; 14(1):230-8. PubMed ID: 17066234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma.
    Olofsson R; Mattsson J; Lindnér P
    Int J Hyperthermia; 2013 Sep; 29(6):551-7. PubMed ID: 23865737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
    Lejeune FJ; Pujol N; Liénard D; Mosimann F; Raffoul W; Genton A; Guillou L; Landry M; Chassot PG; Chiolero R; Bischof-Delaloye A; Leyvraz S; Mirimanoff RO; Bejkos D; Leyvraz PF
    Eur J Surg Oncol; 2000 Nov; 26(7):669-78. PubMed ID: 11078614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.